These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9614013)

  • 61. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
    Rees AL
    J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treating sickle cell anaemia with hydroxycarbamide.
    Pollack S
    Br J Haematol; 2014 Jan; 164(2):296-7. PubMed ID: 24116862
    [No Abstract]   [Full Text] [Related]  

  • 63. Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia.
    McLaren A; Klingel M; Behera S; Odame I; Kirby-Allen M; Grasemann H
    Am J Respir Crit Care Med; 2017 Mar; 195(5):689-691. PubMed ID: 28248149
    [No Abstract]   [Full Text] [Related]  

  • 64. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
    O'branski EE; Ware RE; Prose NS; Kinney TR
    J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
    Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
    Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
    Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
    Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease.
    Mahadeo KM; Oyeku S; Taragin B; Rajpathak SN; Moody K; Santizo R; Driscoll MC
    Am J Hematol; 2011 Sep; 86(9):806-8. PubMed ID: 21850660
    [No Abstract]   [Full Text] [Related]  

  • 69. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea.
    Singh SA; Koumbourlis AC; Aygun B
    Pediatr Blood Cancer; 2008 Jun; 50(6):1258-60. PubMed ID: 18293380
    [TBL] [Abstract][Full Text] [Related]  

  • 70. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 71. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 72. Malignancies in sickle cell disease patients treated with hydroxyurea.
    Ferster A; Sariban E; Meuleman N;
    Br J Haematol; 2003 Oct; 123(2):368-9. PubMed ID: 14531924
    [No Abstract]   [Full Text] [Related]  

  • 73. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 74. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
    Strouse JJ; Heeney MM
    Pediatr Blood Cancer; 2012 Aug; 59(2):365-71. PubMed ID: 22517797
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
    Stettler N; McKiernan CM; Melin CQ; Adejoro OO; Walczak NB
    JAMA; 2015 Apr; 313(16):1671-2. PubMed ID: 25919532
    [No Abstract]   [Full Text] [Related]  

  • 77. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Takahashi Y; Mori J; Tsubokura M; Matsumura T; Kami M
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098851
    [No Abstract]   [Full Text] [Related]  

  • 78. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Obaro SK; Inusa B; Telfer P
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098850
    [No Abstract]   [Full Text] [Related]  

  • 79. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Social media discussions provide new insight about perceptions of hydroxyurea in the sickle cell community.
    Walker AL; Gaydos LM; Farzan R; De Castro L; Jonassaint C
    Am J Hematol; 2019 May; 94(5):E134-E136. PubMed ID: 30734364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.